OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Barry on the Rationale for Using Partial Breast Irradiation in Breast Cancer Management

May 10th 2024

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.

Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation Oncology

May 10th 2024

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

May 10th 2024

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

May 10th 2024

Bradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.

Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCC

May 10th 2024

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

May 10th 2024

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

Dr Chon on Durvalumab Plus Chemotherapy and Olaparib in Endometrial Cancer

May 10th 2024

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

Dr Asare on an AI Model to Predict PFS Outcomes in Ovarian Cancer

May 10th 2024

Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Dr Ignatz-Hoover on Bispecific Antibodies in the Multiple Myeloma Treatment Armamentarium

May 9th 2024

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.

Dr Klisovic on the Impact of Momelotinib on Myelofibrosis Management

May 9th 2024

Rebecca Klisovic, MD, discusses updates with JAK inhibitors, highlighting factors that inform JAK inhibitor selection in myelofibrosis.

Dr Hauschild on Ongoing Research With Adjuvant Immunotherapy in CSCC

May 9th 2024

Axel Hauschild, MD, PhD, discusses research with adjuvant immunotherapy in CSCC and immunotherapy indications in basal cell carcinoma.

Dr Porter on the Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL

May 9th 2024

David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.

Dr Brown on Ongoing Trials Targeting the RAS/MAPK Pathway in Ovarian Cancer

May 9th 2024

Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.

Dr Deng on BTK Inhibitors vs Venetoclax-Based Treatment Regimens in CLL/SLL

May 9th 2024

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Dr Chambers on FDA-Approved PARP Inhibitors in the Ovarian Cancer Treatment Arena

May 8th 2024

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

Dr Cosgrove on the FDA Approval of Mirvetuximab Soravtansine for Frα+ Ovarian Cancer

May 8th 2024

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

Dr Mujumdar on Awareness Initiatives to Address Unmet Needs in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.

Dr Piulats on the Rationale For Evaluating Predictive Biomarkers for Talazoparib/Enzalutamide in mCRPC

May 8th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses the rationale for identifying predictive biomarkers for talazoparib plus enzalutamide in mCRPC.

Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic Malignancies

May 8th 2024

Guenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.